Survival in SMA type I: A prospective analysis of 34 consecutive cases

Neuromuscular Disorders

Volumn 18, Issue 7, 2008, Pages 541-544

  Cobben, J M ^a   Lemmink, H H ^b   Snoeck, I ^c   Barth, P A ^a   van der Lee, J H ^d   de Visser, M ^d  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

SMA I; SMN1 gene; Survival analysis; Werdnig Hoffmann

Indexed keywords

SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 2;

AGE DISTRIBUTION; ARTICLE; CAUSE OF DEATH; CHILDHOOD MORTALITY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INFANT; INFECTION SENSITIVITY; LUNG INFECTION; MALE; MOTOR DEVELOPMENT; NEUROLOGIC EXAMINATION; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; RESPIRATORY FAILURE; SPINAL MUSCULAR ATROPHY TYPE I; STATISTICAL ANALYSIS; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; WERDNIG HOFFMANN DISEASE;

AGE OF ONSET; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; MALE; NERVE TISSUE PROTEINS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD; SURVIVAL ANALYSIS;

EID: 46449121472     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2008.05.008     Document Type: Article

References (15)

1. Munsat T.L. Workshop report International SMA Collaboration. Neuromuscul Disord 1 2 (1991) 81
2. Thomas N.H., and Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord 4 5-6 (1994) 497-502
3. Zerres K., and Davies K. 59th ENMC International Workshop: SMA: recent progress and revised diagnostic criteria. Neuromuscul Disord 9 (1999) 272-278
4. Borkowska J., Rudnik-Schoneborn S., Hausmanowa-Petrusewicz I., and Zerres K. Early infantile form of spinal muscular atrophy (Werdnig-Hoffmann disease) with prolonged survival. Folia Neuropathol 40 1 (2002) 19-26
5. Oskoui M., Levy G., Garland C.J., et al. The changing natural history of spinal muscular atrophy type 1. Neurology 69 20 (2007) 1931-1936
6. Brichta L., Hofmann Y., Hahnen E., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12 19 (2003) 2481-2489
7. Jarecki J., Chen X., Bernardino A., et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 14 14 (2005) 2003-2018
8. Crawford T.O. Concerns about the design of clinical trials for spinal muscular atrophy. Neuromuscul Disord 14 8-9 (2004) 456-460
9. Arkblad E.L., Darin N., Berg K., et al. Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. Neuromuscul Disord 16 12 (2006) 830-838
10. Cobben J.M. DNA-studies in spinal muscular atrophy (1996), Rijksuniversiteit Groningen, The Netherlands
11. Ignatius J. The natural history of severe spinal muscular atrophy-further evidence for clinical subtypes. Neuromuscul Disord 4 5-6 (1994) 527-528
12. Zerres K., Wirth B., and Rudnik-Schoneborn S. Spinal muscular atrophy - clinical and genetic correlations. Neuromuscul Disord 7 3 (1997) 202-207
13. Chung B.H., Wong V.C., and Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics 114 5 (2004) e548-e553
14. Hachiya Y., Arai H., Hayashi M., et al. Autonomic dysfunction in cases of spinal muscular atrophy type 1 with long survival. Brain Dev 5 (2005)
15. Wirth B., Brichta L., Schrank B., et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 119 4 (2006) 422-428